Illumina Inc (ILMN): Jay T Flatley , director of Illumina Inc sold 10,000 shares on Jul 18, 2016. The Insider selling transaction was reported by the company on Jul 20, 2016 to the Securities and Exchange Commission. The shares were sold at $150.00 per share for a total value of $1,500,010.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 15, 2016, A Blaine Bowman (director) sold 5,000 shares at $147.54 per share price.On Jul 12, 2016, Christian O Henry (EVP & Chief Commercial Officer) sold 716 shares at $141.89 per share price.Also, On Jun 15, 2016, Roy A Whitfield (director) sold 3,800 shares at $140.44 per share price.On Jun 3, 2016, Karin Eastham (director) sold 5,000 shares at $145.01 per share price.
Illumina: On Monday, Jul 18, 2016 heightened volatility was witnessed in Illumina which led to swings in the share price. The shares opened for trading at $148.72 and hit $150.2992 on the upside , eventually ending the session at $149.57, with a gain of 0.58% or 0.86 points. The heightened volatility saw the trading volume jump to 7,11,788 shares. The 52-week high of the share price is $242.37 and the company has a market cap of $22,017 M . The 52-week low of the share price is at $127.1.
Company has been under the radar of several Street Analysts.Illumina is Downgraded by Morgan Stanley to Underweight while Lowering the Price Target of the company shares to $ 110 from a previous price target of $130 . Earlier the firm had a rating of Equal-Weight on the company shares. The Rating was issued on Jul 5, 2016.Illumina is Initiated by CL King to Buy. The Rating was issued on Jun 22, 2016.Illumina is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 138 from a previous price target of $150 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 160 from a previous price target of $215 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Canaccord Genuity to Hold while Lowering the Price Target of the company shares to $ 140 from a previous price target of $160 . The Rating was issued on May 4, 2016.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.